Poolbeg Pharma (LON:POLB) Stock Price Up 12.8% – Should You Buy?

Shares of Poolbeg Pharma PLC (LON:POLB) shot up 12.8% during mid-day trading on Friday . The stock traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.30 ($0.07). 1,229,697 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 6,431,729 shares. The stock had previously closed at GBX 4.70 ($0.06).

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.

Poolbeg Pharma Stock Up 16.0 %

The firm has a market capitalization of £27.25 million, a P/E ratio of -545.00 and a beta of 2.11. The stock has a fifty day simple moving average of GBX 6.48 and a 200 day simple moving average of GBX 9.15.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.